Enanta Pharmaceuticals Inc financial data

Symbol
ENTA on Nasdaq
Location
4 Kingsbury Avenue, Watertown, MA
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 524 % -14%
Debt-to-equity 226 % +67.2%
Return On Equity -89 % -39.6%
Return On Assets -27.3 % -0.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.4M shares +0.89%
Common Stock, Shares, Outstanding 21.4M shares +0.93%
Entity Public Float 347M USD -56.6%
Common Stock, Value, Issued 214K USD +0.94%
Weighted Average Number of Shares Outstanding, Basic 21.4M shares +0.93%
Weighted Average Number of Shares Outstanding, Diluted 21.4M shares +0.93%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 64.8M USD -9.94%
Research and Development Expense 114M USD -16.9%
General and Administrative Expense 47.9M USD -17.3%
Costs and Expenses 162M USD -17%
Operating Income (Loss) -96.8M USD +21.2%
Nonoperating Income (Expense) 2.75M USD -42.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -94.1M USD +20.4%
Income Tax Expense (Benefit) -2.06M USD +26.3%
Net Income (Loss) Attributable to Parent -92M USD +20.2%
Earnings Per Share, Basic -4 USD/shares +20.9%
Earnings Per Share, Diluted -4 USD/shares +20.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44.8M USD +25.3%
Accounts Receivable, after Allowance for Credit Loss, Current 8.33M USD +1.92%
Assets, Current 223M USD -22.3%
Property, Plant and Equipment, Net 36.6M USD +46.2%
Operating Lease, Right-of-Use Asset 38.3M USD -7.19%
Other Assets, Noncurrent 94K USD -10.5%
Assets 301M USD -24.5%
Accounts Payable, Current 3.55M USD -66.8%
Employee-related Liabilities, Current 4.77M USD -0.42%
Accrued Liabilities, Current 10.9M USD -15.4%
Liabilities, Current 44.5M USD -23.5%
Operating Lease, Liability, Noncurrent 55.7M USD +15.6%
Other Liabilities, Noncurrent 252K USD +11%
Liabilities 222M USD -11.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -402K USD +38.4%
Retained Earnings (Accumulated Deficit) -386M USD -31.3%
Stockholders' Equity Attributable to Parent 79.3M USD -46.8%
Liabilities and Equity 301M USD -24.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.8M USD +32.8%
Net Cash Provided by (Used in) Financing Activities -4.99M USD +32.2%
Net Cash Provided by (Used in) Investing Activities 68.9M USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 21.4M shares +0.93%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 47.1M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.01M USD -4.3%
Deferred Tax Assets, Valuation Allowance 127M USD +10.5%
Deferred Tax Assets, Gross 141M USD +15.3%
Operating Lease, Liability 58.1M USD +14.8%
Payments to Acquire Property, Plant, and Equipment 8.75M USD +1011%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -91.8M USD +19.8%
Lessee, Operating Lease, Liability, to be Paid 88.2M USD -7.5%
Property, Plant and Equipment, Gross 59.1M USD +17.7%
Operating Lease, Liability, Current 2.39M USD -1.52%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.72M USD +6.06%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.47M USD +383%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +27.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.1M USD -14%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.98M USD +6.09%
Deferred Tax Assets, Operating Loss Carryforwards 7.27M USD +16816%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 905K USD -14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.25M USD +6.09%
Deferred Tax Assets, Net of Valuation Allowance 14.2M USD +87.1%
Share-based Payment Arrangement, Expense 22.2M USD -13.7%
Interest Expense 2.36M USD +17.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%